Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

GSK and Daiichi form vaccines joint venture in Japan

Executive Summary

GlaxoSmithKline PLC--through its GlaxoSmithKline Biologicals SA (vaccines) and GlaxoSmithKline KK (Japanese) divisions--and Daiichi Sankyo Co. Ltd. have established the new 50/50 joint venture, Japan Vaccine Co. Ltd., focused on preventative vaccines.
Deal Industry
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Joint Venture
    • R+D and Marketing-Licensing
    • Includes Equity

Related Companies

Advertisement
UsernamePublicRestriction

Register